- Coronary Stents Coronary Balloons Catheters Guide Wires Introducer Sheaths Accessories Peripheral Interventional Products
- Immunoassay Molecular Diagnostics Hematology Diagnostics POCT Lab Solution
- Structural Heart Diseases Products
- Vascular Access Blood Pressure Transducer Arterial Blood Sampler CVC Accessories IV Catheter Needle-free Connectors Insulin Injection Pain Relief
- Hemodialysis consumables Hemoperfusion Cartridge Dialysis machine
- ECG Patient Monitor Oximeter
- Cardiovasculars Oncology Anti-infectives Central Nervous System Others
- Endoscope Endoscopic Ultrasound System
- Trauma Implant Spinal Implant Artificial Joint Sports Medicine
- Pacemakers and Leads Equipments
- Metabolic Diseases Cardiovascular Diseases
- ELISA CLIA FIA
- Nucleic Acid Extraction Nucleic Acid Extraction ＆ PCR Kits Real-Time PCR
- Thrombelastography Analyzer Blood Grouping Platelet Aggregation
- POCT - FIA Colloidal Gold
- NeoECG Holter Monitor Portable ECG Monitor AI-ECG Pocket ECG
- Patient Monitor Vital Signs Monitor End-tidal Capnography
- Fingertip Oximeter Handheld Oximeter Wrist Oximeter Wearable Oximeter All-in-One Health Monitor POCT Solution
- OBS Locking Compression Plate Locking Plates Conventional Plates Mini Plates System Screws Patella Ring - Patented Product Metal Pins Cable System
- Internal Fixation System Laminoplasty Plate System Percutaneous Kyphoplasty Fusion Cage Cervical Fixation System
- Hip System Knee System
- Suture Anchor Suture Button
Clinical Trials
View on ClinicalTrials.gov
Development Highlights
1. Targeting Liver–Adipose Signaling
An investigational siRNA designed to silence hepatic INHBE expression and reduce Activin E production, modulating liver–adipose signaling to explore a non-incretin approach to obesity treatment.
2. Potential to Improve Body Composition
Supported by human genetic evidence and preclinical findings, MWN117 is being investigated for its potential to reduce visceral fat and improve body composition.
3. Potential to Complement Incretin-Based Therapies
Preclinical findings support further investigation of MWN117 alongside GLP-1 receptor agonists, with the aim of achieving additional fat loss while preserving muscle mass.
For licensing and partnership inquiries, please contact us (bd@lepu-medical.com).
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
